Daily Stock List
Graymark Healthcare, Inc. (GRMH)
StreetInsider, OTCPicks, SmallCap Voice, Daily Markets, and PennyOmega reported earlier on Graymark Healthcare, Inc. (GRMH), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Oklahoma City, Oklahoma, Graymark Healthcare, Inc. is the nation's second largest provider of sleep management solutions. They diagnose and treat more than 80 sleep disorders. The Company also specializes in complete care for Obstructive Sleep Apnea (OSA). Graymark also sells equipment and related supplies and components used to treat sleep disorders. Graymark Healthcare lists on the NASADQ Capital Market.
The Company offers their services through 107 sleep laboratories primarily in the Midwest. These include standalone or IDTF facilities, therapy facilities, rural outreach hospital sites and urban hospital management agreements.
In August, Graymark Healthcare and Foundation Healthcare Affiliates, LLC jointly announced the signing of a definitive agreement for Graymark to acquire 100 percent of the equity interest of Foundation Surgical Hospital Affiliates, LLC, and Foundation Surgery Affiliates, LLC from Foundation Healthcare Affiliates in a transaction valued at $1.10 per common share for an aggregate transaction value of approximately $52.5 million.
The transaction has been approved by the Boards of Directors of both companies. The transaction is targeted to close in this third quarter 2012, subject to the finalization of related ancillary agreements and the satisfaction of specified closing conditions and third-party consents. Foundation/Graymark will be the name post closing.
Furthermore, in August, Graymark Healthcare reported financial results for the second quarter ended June 30, 2012. Net revenues in the second quarter of 2012 were $4.3 million, decreasing 2.2 percent from $4.4 million in the second quarter of 2011. Loss from continuing operations, net of taxes, were $5.3 million in the second quarter of 2012. This is in comparison to a loss from continuing operations of $1.1 million in the year-ago quarter. Net loss attributable to Graymark was $5.3 million or $(0.34) per share in the second quarter of 2012, compared to a net loss of $0.6 million or $(0.07) per share in the prior year quarter.
Graymark Healthcare, Inc. (GRMH), closed Tuesday’s trading session at $0.50, up 19.05%, on 75,071 volume with 57 trades. The average volume for the last 60 days is 19,955 and the stock's 52-week low/high is $0.276/$1.20.
Attitude Drinks, Inc. (ATTD)
OTCPicks, Stock Twiter, and Penny Stock Rumble reported recently on Attitude Drinks, Inc. (ATTD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Palm Beach Gardens, Florida, Attitude Drinks, Inc. is an innovative beverage, brand development, and marketing company. They focus on delivering experiential, functional, and healthful beverages. The Company offers Phase III Recovery, a milk-based protein drink. The primary target for Phase III Recovery is active sports minded males and females from ages 15 to 35. However, the Company will target active sports and exercise consumers at all levels. Attitude Drinks shares trade on the OTC Bulletin Board.
The Company’s plan of operation during the coming months is to focus on the non-alcoholic single serving beverage business. This involves the development and marketing of milk based products in two fast growing segments - sports recovery and functional dairy. Attitude Drinks does not directly manufacture their products. They outsource the manufacturing process to third party bottlers and contract packers.
The Company’s current product is a dairy based product - Phase III Recovery. The design of this product is for the third phase of exercise, the "after phase" of before, during, and after. This product is the first milk based protein drink ever to be produced in the United States. It is shelf-stable with a twelve month long shelf life.
Attitude Drinks started to sell this new product in February of 2010. The Company’s co-pack partner is O-AT-KA Milk Products. O-AT-KA is the largest retort milk processor in the U.S., located in Batavia, New York. O-AT-KA has the most advanced retort processor and expertise to produce this product with state-of-the-art milk filtration systems and the packaging of this product in new Ball Container aluminum eco-friendly re-sealable bottles.
Attitude Drinks anticipates the development of other dairy based drink products in late 2012 or early 2013. Their intention is to concentrate on the largest markets in the eastern U.S., with further expansion in the fifteen largest markets of the country. The Company will pre-sell in four sales channels. These four are grocery, convenience, drug and sports, and gym specialty. Attitude Drinks intention is to develop important working partnerships with regional Direct Store Delivery (DSD) beverage distributors in these markets.
Attitude Drinks, Inc. (ATTD), closed today at $0.0005, even with yesterday's close, on 26,314,367 volume with 39 trades. The average volume for the last 60 days is 7,325,119 and the stock's 52-week low/high is $0.0001/$0.0093.
Brazil Resources, Inc. (BRIZF)
FutureMoneyTrends.com, StockProfessors, PennyStockShark, and ShazamStocks reported recently on Brazil Resources, Inc. (BRIZF), The Green Baron, Stockdigest Report, Research Driven Investor, Growing Stocks Reports, Michael Stone, PickPennyStocks, CrushTheStreet.com did earlier, and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Brazil Resources, Inc. is a mineral exploration company with corporate headquarters in Vancouver, British Columbia. The Company focuses on the acquisition and development of projects in emerging producing gold districts in Brazil and other parts of South America. Brazil Resources has their Montes Aureos, Trinta, and Maua Gold Projects located in the State of Maranhao, Brazil, within the Gurupi gold belt. The Company’s shares trade on the OTCQX International (BRIZF) and on the TSX Venture Exchange (BRI.V).
Currently, Brazil Resources is advancing their flagship Cachoeira project. This project has a combined resource of 667,300 ounces of gold. Additionally, the Company has their Artulandia gold project located in the Goais State, in central Brazil. The Company has a team that has discovered and developed more than 10 Moz in Brazil.
Cachoeira has an NI 43-101 indicated mineral resource of 446,000 ounces of gold at 1.11 g/t Au and an inferred resource of 221,300 ounces of gold at 1.27 g/t Au. Cachoeira is in the Gurupi Gold Belt in close proximity to Montes Áureos, Trinta, and Maua. Cachoeira has excellent infrastructure and is situated along a major highway in Brazil; it covers 4,742 hectares of land.
The Montes Áureos project area has been mined for gold over the past 150 years. It is within 20 km of the Chega Tudo and Cipoeiro projects, a 3Moz deposit. Artisanal mining, sampling, trenching, auger drilling, as well as historic drilling indicate the potential for a large, near-surface gold resource.
Today, Brazil Resources announced that, further to their news release dated July 11, 2012, the Company has completed the acquisition of a 100 percent interest of the Cachoeira gold project, located in Pará State, Brazil, from Luna Gold Corp. The transaction was completed under the terms of the previously announced share purchase agreement dated July 10, 2012 between Brazil Resources and Luna, whereby Brazil Resources has acquired all of the issued and outstanding shares of Luna Gold (International) Corp., a wholly-owned subsidiary of Luna, which owns an indirect 100 percent interest in the Cachoeira Project.
Brazil Resources, Inc. (BRIZF), closed Tuesday’s trading session at $1.1520, down 1.87%, on 11,900 volume with 9 trades. The average volume for the last 60 days is 5,253 and the stock's 52-week low/high is $0.7485/$1.52.
Gold Dynamics Corp. (GLDN)
Pumps and Dumps, PSSMS Newsletter, and Stock Exploder reported this month on Gold Dynamics Corp. (GLDN), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Founded in 2006, Gold Dynamics Corp. is a precious metals explorer whose shares trade on the OTC Bulletin Board. The Company focuses on underexplored regions of the world and is working on building gold and silver mineral resources through systematic exploration. The Company has a highly experienced board and management team consisting of professionals with significant development and mine management experience.
Gold Dynamics looks to identify, acquire, and develop deposits that have the potential to be world class and in an acceptable risk environment. In March 2012, Gold Dynamics acquired by option the Hoyle North property in the prolific Timmins gold mining camp in Ontario.
The Hoyle North property consists of 32 claim units which represent approximately 12 square kilometers. Gold Dynamics will acquire 100 percent of the property for cash payments over 3 years amounting to $95,000.00 and work expenditures totaling $110,000.00 with a 2 percent Net Smelter Return (NSR) granted to the vendors. The property is near the west end of the Neo-Archean Abitibi greenstone belt, approximately 18 km northeast of Timmins, Ontario, and 6 kilometers north of the Porcupine-Destor fault.
The area of acquisition is world renowned as a heavily mineralized area with several active mines where as much as 85 million ounces of gold have been mined historically. The Hoyle North property remains relatively unexplored near to expansive mining and exploration efforts by significant companies such as Goldcorp, Xstrata, Lakeshore Gold, and San Gold, Osisko Mining and VG Gold and others.
Earlier this month, Gold Dynamics’ Chief Executive Officer and President, Mr. Gary Kirk, announced that the threshold of developmental expenditures required by the Ministry of Northern Mines and Development for Ontario for the Company's Hoyle North project has been surpassed. The requisite filings to hold the claims in good standing will be made by the October 3, 2012 filing date as required.
Mr. Kirk said, “I am extremely pleased with our summer sampling program and all indications are that we have gained the rights to a very mineralized property, our objective remains to confirm a parallel or offshoot zone from the historic Destor-Porcupine Fault. To date we have discovered 56 minerals including precious metals, base metal and Rare Earth Elements in our samples.”
Gold Dynamics Corp. (GLDN), closed Tuesday’s trading session at $0.0160, up 14.29%, on 49,500 volume with 4 trades. The average volume for the last 60 days is 59,806 and the stock's 52-week low/high is $0.01/$0.088.
Royal Standard Minerals, Inc. (RYSMF)
AllPennyStocks reported earlier on Royal Standard Minerals, Inc. (RYSMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Royal Standard Minerals, Inc. is a junior mining and exploration company with corporate headquarters in Toronto, Ontario. The Company engages in the acquisition, exploration, and development of gold and precious metal deposits in the state of Nevada. Royal Standard has multiple high quality gold projects in Nevada. Founded in 1986, Royal Standard Minerals lists on the OTC Bulletin Board.
The Company's flagship Goldwedge Mine is southeast of the Round Mountain gold mine in central Nevada. Royal Standard's current portfolio of gold exploration projects includes Fondaway Canyon, Pinon, and Dixie Comstock.
The Goldwedge Mine is located approximately 35 miles NE of the town of Tonopah, in west-central Nevada. The Goldwedge Mine contains an NI 43-101 compliant gold resource that the Company believes has excellent potential to grow with further exploration and development. The existing recognized resource covers a strike length of approximately 1,100 feet, with a drill tested vertical extent of more than 500 feet.
The Company’s Fondaway Canyon contains a high-grade, gold-bearing vein system approximately 11,000 feet long. The property covers 148 contiguous claims, or approximately 2960 acres, approximately 40 miles east of Reno, Nevada on the western slopes of the Stillwater Range. Royal Standard’s Pinon Project lies 10 miles south of the Rain Mine operated by Newmont Mining Corp. The Dixie Comstock Project consists of 1446 acres of mineral rights in Dixie Valley, Churchill County, in northern Nevada.
At the end of August, Royal Standard Minerals announced that they entered into a non-binding Letter Of Intent (LOI) with Scorpio Gold Corp. (SGN.V) to sell their Goldwedge, Pinon and Fondaway Canyon property interests to Scorpio in consideration for $2.5 million in cash, 17.5 million shares of Scorpio, and the assumption by Scorpio of approximately US$12 million in principal and all interest, fees and other amounts due on such principal currently owing by Royal Standard to Waterton Global Value, L.P., the Company's principal creditor.
Pursuant to the LOI, Scorpio provided a $250,000 refundable advance deposit to Royal Standard and agreed to advance an additional $100,000 per month until closing.
Royal Standard Minerals, Inc. (RYSMF), closed Tuesday’s trading at $0.072, up 2.86%, on 71,750 volume with 4 trades. The average volume for the last 60 days is 33,380 and the stock's 52-week low/high is $0.05/$0.30.
American Eagle Energy Corp. (AMZG)
SmallCapVoice reported earlier on American Eagle Energy Corp. (AMZG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Incorporated in 2003, American Eagle Energy Corp. is an independent oil exploration and production company with headquarters in Littleton, Colorado. The Company’s dedication is to the acquisition and development of energy resources in North America. The Company formerly went by the name Eternal Energy Corp. They changed their name to American Eagle Energy Corp. in December 2011 upon the completion of their acquisition of American Eagle Energy, Inc.
Since their inception, American Eagle Energy has entered into participation agreements related to oil and gas exploration projects throughout the continental U.S., including Colorado, Montana, Nevada, North Dakota, Texas, and Utah, and in the province of Saskatchewan, Canada, and areas located in the North Sea. As of June 30, 2012, the Company is actively engaged in exploration activities within the Spyglass Property, located in Divide County, North Dakota; within the Benrude Property, located in Roosevelt County, Montana, and within the Hardy Property, located in southeastern Saskatchewan.
Additionally, American Eagle Energy owns undeveloped acreage interests in the Glacier Prospect, located in Toole County, Montana; the Sidney North Prospect, located in Richland County, Montana, and the West Spyglass Prospect, located in an area adjacent to the Company’s Spyglass Property in Divide County, North Dakota and Sheridan County, Montana.
Since November 2010, American Eagle Energy has elected to participate as a non-operating working interest partner in the drilling of 25 wells within the Spyglass Property and areas within Divide Country. Their consolidated working interest ownership in the wells ranges from 0.03 percent to 22.87 percent.
During this same period, the Company has drilled and completed six wells, in which they own significant working interests, and for which they serve as the Operator. Two of the wells were drilled within their Hardy Property, located in southeastern Saskatchewan. The other four wells were drilled within their Spyglass Property. Moreover, the Company has reworked an existing well, located within the Hardy Property. They anticipate drilling and completing six more wells within the Spyglass Property during the remainder of 2012. The Company’s working interests in these wells ranges from 6.43 percent to 85.00 percent.
American Eagle Energy Corp. (AMZG), closed Tuesday’s session at $0.699, up 9.22%, on 18,604 volume with 8 trades. The average volume for the last 60 days is 14,639 and the stock's 52-week low/high is $0.56/$1.75.
P2 Solar, Inc. (PTOS)
OTCPicks and FeedBlitz reported earlier on P2 Solar, Inc. (PTOS), AlphaTrade did previously, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Formed in March 2009, P2 Solar, Inc. is a development stage company whose shares trade on the OTC Bulletin Board. Their current business operations focus on solar panel technology, and the potential construction of a solar power plant located in India, Bulgaria, and Ontario, Canada. The Company, via their ownership interest in Solarise Power, Inc., a privately owned Nevada corporation, involves in the research and development (R&D) of solar panel technology. P2 Solar is based in Surrey, British Columbia.
Solarise’s specialty is the development of solar panel technology, utilizing the JIL Technology. P2 Solar, by way of Solarise, is currently testing the hybrid panel containing the JIL Technology internally. Once the internal tests are completed the panel will be sent for independent testing and power certification with Intertek Laboratories in California.
P2 Solar’s management set out a three phase program from 2011 to 2013 with an aggressive mandate to develop 100 MW of sustainable, renewable PV solar power capacity by the end of 2013. The Company's areas of focus are the aforementioned regions and P2 Solar is currently working to identify and execute potential PV solar projects in these regions.
Concerning recent achievements, P2 Solar executed an agreement to develop a 7.3 MW solar project in Bulgaria. They also formed an agreement with Photonix Solar PVT., a solar PV module manufacturer in Pune, India. The Company has expanded their Senior Management Team, and appointed a Consultant in India to assist with the development of India solar projects. In addition, P2 Solar appointed a Consultant in Europe to assist with the development of European solar projects, and they signed a 1 year marketing agreement with MUNC Media to assist with expanding the Company’s public awareness.
Earlier this month, P2 Solar reported that in the June 2012 Shareholder newsletter the Company indicated that they would refocus their efforts towards developing solar PV projects in India. The Company has made progress in this direction; they’ve developed a number of opportunities, which are now being reviewed, following a recent visit to India by part of their management team.
The first opportunity is a 1 MW project under one of the state level solar PV programs. P2 Solar is undertaking due diligence on the state program. The Company has secured several good sites. The project size is small; however it does provide some opportunity for obtaining agreements for additional larger scale projects in the future. Commissioning of the 1 MW would be during the first half of 2013.
P2 Solar, Inc. (PTOS), closed Tuesday’s trading session at $0.015, even for the day, on 1,000 volume with 1 trade. The average volume for the last 60 days is 23,967 and the stock's 52-week low/high is $0.012/$0.095.
ADVENTRX Pharmaceuticals, Inc. (ANX)
Greenbackers, The Street, SmarTrend Newsletters, Profit Confidential, Wall Street Resources, StockEgg, MadPennyStocks, PennyInvest, StockRich, CoolPennyStocks, HotOTC, PennyStockVille, and BullRally reported earlier on ADVENTRX Pharmaceuticals, Inc. (ANX), and we highlight the Company, here at the QualityStocks Daily Newsletter.
ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. Their lead product candidate, ANX-188 (purified poloxamer 188), has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function that is compromised in a broad spectrum of serious and life-threatening diseases and conditions. ADVENTRX Pharmaceuticals has their headquarters in San Diego, California.
ANX-188 is a rheologic, antithrombotic, and cytoprotective agent. It improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease.
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188, or P188, is a nonionic, block copolymer that has been found to improve microvascular blood flow. It does this by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces.
In December 2011, ADVENTRX announced that they met with the U.S. Food and Drug Administration (FDA) to discuss their overall development plans for ANX-188, and the design of a phase 3 study for the treatment of patients with sickle cell disease. ADVENTRX has since had more interaction with the FDA and with key opinion leaders in sickle cell disease, and they continue to develop the trial design. Additional work is necessary to finalize the protocol and primary endpoint. ADVENTRX plans to initiate a phase 3 study of ANX-188 in patients with sickle cell disease this year.
The Company’s other programs include Exelbine™ (vinorelbine injectable emulsion), or ANX-530. This is a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®). ADVENTRX is seeking a partner or outside investor to continue development of the Exelbine program. In addition, ADVENTRX has their ANX-514 (docetaxel for injectable emulsion). This is a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel.
Earlier this month, ADVENTRX Pharmaceuticals announced that Ted W. Love, M.D., has joined their Board of Directors. Dr. Love most recently served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc. There, he launched four multi-center, global phase 3 studies in two years and played a key role in obtaining in 2012 accelerated approval from the FDA to market Kyprolis™ (carfilzomib).
ADVENTRX Pharmaceuticals, Inc. (ANX), closed Tuesday’s session at $0.83, up 4.85%, on 3,578,429 volume with 3,370 trades. The average volume for the last 60 days is 772,840 and the stock's 52-week low/high is $0.45/$1.16.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.29, up 7.41%, on 580,269 volume with 95 trades. The stock’s average daily volume over the past 60 days is 86,385, and its 52-week low/high is $0.21/$0.85.
International Stem Cell Corp. reported that the United States Patent and Trademark Office granted a patent for a key element of the company's metabolic liver disease program, their method for creating pure populations of definitive endoderm (precursor cells to liver and pancreas cells) from human pluripotent stem cells. The company can now produce the quantities of precursor cells needed for the program in a cost-effective and efficient manner, adding yet another patent to the growing portfolio of proprietary technologies related to the development of treatments for incurable diseases using human parthenogenetic (unique pluripotent stem cells) stem cells.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Granted Key Patent for Liver Disease Program
International Stem Cell Corp Subsidiary Lifeline Skin Care Announces Entry Into Chinese Market
International Stem Cell Corp to Participate in Upcoming Investor Conferences
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.09, even with yesterday's close, on 1,117,250 volume with 1 trades. The stock’s average daily volume over the past 60 days is 108,250, and its 52-week low/high is $0.001/$0.018.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Consorteum Completes Acquisition of Tarsin Inc.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $1.33, off by 1.48%, on 94,447 volume with 54 trades. The stock’s average daily volume over the past 60 days is 17,831, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Memorandum of Agreement to Open Pharmaceutical Plant for the Production of IRT-103 (LDN)
Dr. Ronald Herberman Joins TNI BioTech Inc. as Senior Vice President of Research and Development and Chief Medical Officer
TNI BioTech, Inc. Acquires Portfolio of Exclusive Licenses to the Portfolio of Patents of Dr. Bernard Bihari
Skinny Nutritional Corp. (SKNY)
The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.006, off by 2.44%, on 1,900,706 volume with 22 trades. The stock’s average daily volume over the past 60 days is 1,556,855, and its 52-week low/high is $0.004/$0.041.
Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.
The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.
The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.
Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer
Skinny Nutritional Corp. Blog
Skinny Nutritional Corp. News:
Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration
Skinny Nutritional Corp. Enters Into $15M Financing, Positions Company to Grow Skinny Brand Portfolio Nationally
Today before the opening bell, International Stem Cell Corporation announced that the United States Patent and Trademark Office (USPTO) awarded the company with a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. Allowing the production of necessary quantities of precursor cells in a more efficient and cost effective manner, this new patent is a key part of ISCO’s metabolic liver disease program.
The patent, 8,268,621, adds to the company’s growing intellectual property portfolio relating to the development of potential treatments for diseases without cure using human parthenogenetic Stem Cells (hpSC). These unique pluripotent stem cells offer the possibility of reducing the cost of health care while avoiding the ethical issues of using fertilized human embryos. In addition to supporting the company’s current liver disease program, this new patented method can be used as a way of creating pancreatic and endocrine cells for use in future studies of diabetes and other metabolic disorders.
According to today’s press release, ISCO has the largest collection of hpSC, including cell lines which immune-match millions of individuals and potentially reduce tissue rejection issues. The company is focusing its therapeutic development efforts on three clinical applications where cell and tissue therapy is already proven but where there currently is an insufficient supply of safe and efficacious cells: Parkinson’s disease, inherited/metabolic liver diseases, and corneal blindness.
For additional information on ISCO, visit the company’s website at www.InternationalStemCell.com
Leveraging the body’s own immune system to fight disease is one of the hottest areas in medicine. The human immune system, by its nature, is able to identify and fight disease organisms in sophisticated ways that chemicals and other traditional interventions by themselves cannot. The first human vaccines, developed in the late 1700s, represented early steps in manipulating the human immune system, and resulted in the saving of countless lives over the past two centuries. Today newly developed technologies have again opened a door to a world of immune system potential.
Florida-based TNI BioTech is in the forefront of combating fatal diseases through the activation and mobilization of the body’s immune system. The company uses patented immunotherapy to harness the power of the immune system in the fight against cancer, infections, and autoimmune diseases. Methionine Enkephalin (MENK), for example, is a human hormone produced naturally by the human immune system. It is believed that MENK is toxic to tumor cells but does not hurt the human body.
TNI BioTech currently lists three primary products:
• IRT-101 is an active immunotherapy that stimulates a patient’s immune system against infectious diseases and tumor cells by increasing the number of T cells and NK cells, NKT and Gammadelta T cells, which destroy infective organisms and tumor cells while simultaneously inhibiting Treg cells.
• IRT-102 is an adaptive immunotherapy that isolates and enriches a patient’s own immune cells. Following an enriching external incubation, cells are transfused back into the patient, providing the patient with a passive immunity containing large amounts of auto-amplified immune cells that combat cancer cells.
• IRT- 103 is an active immunotherapy that activates a patient’s immune system against HIV/AIDS and tumor cells. This is accomplished by activating the enkephalin receptor system, resulting in an increased number of T cells and NK cells that destroy infective organisms and tumor cells.
TNI BioTech also intends to investigate the following areas of application:
• Autoimmune states such as rheumatoid arthritis and multiple sclerosis
• As an adjuvant to vaccines in the protection from getting infectious diseases
• In patients undergoing chemotherapy or radiation treatments in surgery
• In wound healing, herpes, and shingles in the elderly.
To learn more about the company, visit www.tnibiotech.com
When Zacks Investment Research recently initiated coverage on Duma Energy, giving the company an Outperform rating based upon its profitability and rapidly growing revenue, it was a vote for the company’s overall strategy of supporting less certain exploratory efforts with an established and predictable flow of income from domestic producing wells. Instead of the common condition of energy exploration companies, founded upon little more than a loan and some prospects, Duma has put together a team of industry pros experienced enough to know a smarter way. By successfully identifying and developing a series of producing wells, primarily in the shallow waters of Houston’s Galveston Bay and Trinity Bay, Duma has built up a dependable source of income.
Duma produced 38,000 barrels of oil equivalent (boe) in fiscal 2011, and produced over 45,000 boe in the first half of fiscal 2012, with year-over-year revenue growth exceeding 500%. With operating margins already approaching 50%, and improving as new wells and production efficiencies increase, the company’s financial foundation continues to grow. They are now sitting on over $77 million in proven reserves (discounted), with less than $12 million booked reserves.
It’s an income stream that has provided Duma the time and backing to explore at their own pace, letting them apply their well-established geological expertise and industry contacts to opportunities overlooked or unavailable to others. An example is their recent acquisition of Namibia Exploration, now a wholly owned subsidiary, giving Duma a working interest in a 5.3 million acre petroleum concession in Namibia, Africa. The Owambo Basin, site of the concession, extends into Angola, one of the continent’s major oil producing countries. The Basin appears to have the elements of a major petroleum system.
For more information on Duma Energy Corp., please visit the company’s website at: www.DUMA.com
DragonWave, a prominent supplier of packet microwave radio systems for mobile and access networks worldwide, announced today that field tests have been completed on its Horizon packet microwave products and the results have confirmed the functionality of higher modulation modes up to 2048 QAM. The tests were conducted in Odessa, Ukraine, the nation’s south Bay City. DragonWave worked in coordination with its in-country partner UKROM and their customer, Intertelecom, on the deployments and analysis for the field test. Intertelecom is one of the largest wireless service providers in the country.
Throughout field-testing, the higher modulation of the Horizon products established the radios’ ability to transport as much as 37 percent more data through existing microwave channels. An improvement of this magnitude will significantly improve spectral efficiency, as well as lower the operator’s cost per bit. The testing was done in concert with dual channel operation and DragonWave’s unique Bandwidth Accelerator feature. These two features, in conjunction with the higher modulation, more than tripled the capacity to more than 1.3 Gbps in this test.
DragonWave is the first packet microwave supplier to offer the cutting edge 2048 QAM radios. These improved radios provide mobile operators tested and proven radios with significantly more total link capacity compared to competitive products. A simple software download is all it takes for customers to acquire this new capability. All Horizon packet microwave radios support Hitless Automatic Adaptive Modulation, bringing operators the benefits of increased capacity by using higher modes when link properties permit-even on existing links that have been designed for lower modulation modes.
To date, DragonWave has shipped over 800 Horizon links to Intertelecom through its local integration partner, UKRCOM.
“We explored other options for increasing link capacity such as XPIC, but we soon realized that DragonWave’s solution of coupling higher modulation modes with Hitless Automatic Adaptive Modulation allows us to meet the growing backhaul demands without needing to re-engineer existing links or purchase additional radios,” said Boris Akulov, CEO at Intertelecom. “In effect, we have found a very cost efficient and streamlined means to triple our network capacity.”
With 2048 QAM, customers can achieve greater than 500 Mbps of transport in a Horizon Compact+ all-outdoor system and up to 1 Gbps when DragonWave’s Bandwidth Accelerator compression technology is included. Horizon Quantum can deliver two carriers per radio, each capable of higher order modulation and compression, delivering up to 2 Gbps in a single radio.
“The successful field testing of 2048 QAM marks another milestone in DragonWave being first to market with technology and innovation that sets us apart from the competition,” said DragonWave CEO Peter Allen. “We congratulate our Ukrainian customers on their performance results and are encouraged to be expanding our market share in an important and growing region for microwave transport.”
For further information, please visit www.intertelecom.ua
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News